In order to dissect the mechanisms by which therapeutic vaccinations using Xcl1 fusion proteins showed better tumor control, B16.OVA tumors from mice immunized as described in Figure 3B, were harvested 10 days post vaccination in order to quantify TILs and characterize their functionality. This evidence concerns the gene XCL1 and neoplasm.